Genomic predictors of prostate cancer therapy outcomes.

Publication Type:

Journal Article

Source:

Expert review of molecular diagnostics, Volume 10, Issue 5, p.619-36 (2010)

Keywords:

2010, Animals, Center-Authored Paper, Clinical Research Division, Epigenesis, Genetic, Gene Expression Profiling, Genome, Human, GENOMICS, Human Biology Division, Humans, Male, MICRORNAS, Mutation, Oncogene Proteins, Fusion, Prostatic Neoplasms, PTEN Phosphohydrolase, Treatment Outcome

Abstract:

Although numerous attempts have been made to forecast outcomes for prostate cancer after therapy using clinical and histological variables, the ability to accurately predict an individual's response to a specific treatment remains elusive. Recently, major advances in the field of genomics have made possible the near-comprehensive assessment of the genetic status of tumor genomes, with major concentration on predicting an individual's response to a specific treatment. Genomic approaches to treatment response include, but are not limited to, detection of gene rearrangements, DNA copy-number aberrations, single-nucleotide polymorphisms, epigenetic changes and differential gene-expression patterns. These approaches have been used to predict response to treatment for local and systemic disease in multiple small cohorts. Further study with larger cohorts and longer follow-up should result in more concordance among genomic approaches, and will enable physicians to gain insight into the heterogeneity of supposedly 'similar' cancers and help tailor treatments accordingly.